185 related articles for article (PubMed ID: 11192477)
1. Chiral bioequivalence: effect of absorption rate on racemic etodolac.
Boni JR; Korth-Bradley JM; Richards LS; Chiang ST; Hicks DR; Benet LZ
Clin Pharmacokinet; 2000 Dec; 39(6):459-69. PubMed ID: 11192477
[TBL] [Abstract][Full Text] [Related]
2. An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies.
García-Arieta A; Abad-Santos F; Rodríguez-Martínez MA; Varas-Polo Y; Novalbos J; Laparidis N; Gallego-Sandín S; Orfanidis K; Torrado J
Chirality; 2005 Oct; 17(8):470-5. PubMed ID: 16104026
[TBL] [Abstract][Full Text] [Related]
3. Quantification of Etodolac in Human Plasma for Pharmacokinetics and Bioequivalence Studies in 27 Korean Subjects.
Song ID; Kang JS; Kim HJ; Kim SM; Zhao DX; Kim SH; Chun MY; Lee KH
Drug Metab Lett; 2017; 10(4):286-294. PubMed ID: 28093968
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.
Lorier M; Magallanes L; Ibarra M; Guevara N; Vázquez M; Fagiolino P
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):787-793. PubMed ID: 26590950
[TBL] [Abstract][Full Text] [Related]
5. Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies.
Torrado JJ; Blanco M; Farré M; Roset P; García-Arieta A
Eur J Clin Pharmacol; 2010 Jun; 66(6):599-604. PubMed ID: 20195587
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability and bioequivalence of two formulations of etodolac (tablets and suppositories).
Molina-Martinez IT; Herrero R; Gutiérrez JA; Iglesias JM; Fábregas JL; Martinez-Tobed A; Cadorniga R
J Pharm Sci; 1993 Feb; 82(2):211-3. PubMed ID: 8445537
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats.
Shi JM; Lai SG; Xu CJ; Duan GL; Li D
Acta Pharmacol Sin; 2004 Aug; 25(8):996-9. PubMed ID: 15301730
[TBL] [Abstract][Full Text] [Related]
8. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
Fornasini G; Monti N; Brogin G; Gallina M; Eandi M; Persiani S; Bani M; Della Pepa C; Zara G; Strolin Benedetti M
Chirality; 1997; 9(3):297-302. PubMed ID: 9176996
[TBL] [Abstract][Full Text] [Related]
9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence study of a fixed dose combination tablet containing rabeprazole and diclofenac sodium in healthy Indian subjects.
Mukherjee J; Das A; Chakrabarty US; Sahoo B; Sengupta P; Chatterjee B; Roy B; Pal TK
Arzneimittelforschung; 2010; 60(8):506-9. PubMed ID: 20863007
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective HPLC-DAD method for the determination of etodolac enantiomers in tablets, human plasma and application to comparative pharmacokinetic study of both enantiomers after a single oral dose to twelve healthy volunteers.
Hewala II; Moneeb MS; Elmongy HA; Wahbi AA
Talanta; 2014 Dec; 130():506-17. PubMed ID: 25159440
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
[TBL] [Abstract][Full Text] [Related]
13. Influence of severity of chronic inflammatory joint disease on the pharmacokinetics of indomethacin and etodolac.
Pawlotsky Y; Le Dantec P; Jacquelinet C; Lapicque F; Goasguen J; Perdriger A; Veillard E; Guggenbuhl P; Netter P
Rev Rhum Engl Ed; 1996 Mar; 63(3):179-87. PubMed ID: 8731235
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers.
Galán-Herrera JF; Poo JL; Maya-Barrios JA; de Lago A; Oliva I; González-de la Parra M; Jiménez P; López-Bojórquez E; Burke-Fraga V; Namur S
Clin Ther; 2008 Sep; 30(9):1667-74. PubMed ID: 18840372
[TBL] [Abstract][Full Text] [Related]
15. Enantioselective analysis of etodolac in human plasma by LC-MS/MS: Application to clinical pharmacokinetics.
de Miranda Silva C; Rocha A; Tozatto E; da Silva LM; Donadi EA; Lanchote VL
J Pharm Biomed Anal; 2016 Feb; 120():120-6. PubMed ID: 26723001
[TBL] [Abstract][Full Text] [Related]
16. Analysis of flurbiprofen, ketoprofen and etodolac enantiomers by pre-column derivatization RP-HPLC and application to drug-protein binding in human plasma.
Jin YX; Tang YH; Zeng S
J Pharm Biomed Anal; 2008 Apr; 46(5):953-8. PubMed ID: 18329215
[TBL] [Abstract][Full Text] [Related]
17. Piroxicam immediate release formulations: A fasting randomized open-label crossover bioequivalence study in healthy volunteers.
Helmy SA; El-Bedaiwy HM
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):466-71. PubMed ID: 27129120
[TBL] [Abstract][Full Text] [Related]
18. Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.
de Miranda Silva C; Rocha A; Tozatto E; da Silva LM; Donadi EA; Dalla Costa T; Lanchote VL; Schmidt S; Bulitta JB
AAPS J; 2017 Nov; 19(6):1814-1825. PubMed ID: 28875479
[TBL] [Abstract][Full Text] [Related]
19. Etodolac clinical pharmacokinetics.
Brocks DR; Jamali F
Clin Pharmacokinet; 1994 Apr; 26(4):259-74. PubMed ID: 8013160
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate.
Lötsch J; Muth-Selbach U; Tegeder I; Brune K; Geisslinger G
Br J Clin Pharmacol; 2001 Oct; 52(4):387-98. PubMed ID: 11678782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
